title: [Diabetes, hypertension and microalbuminuria in primary care].
abstract: Microalbuminuria has been widely appreciated in recent years to be a valuable risk marker for an increased cardiovascular disease morbidity and mortality. Thus guidelines for the treatment of type-2-diabetes in Germany and the US recommend an annual screening as soon as the diagnosis of diabetes is established and a quarterly control when microalbuminuria is present. While nationally representative epidemiologic data from the US have been available, data from Germany, especially from the primary care sector are missing. This is especially important in light of the gatekeeper function of the primary care physician. The "Hypertension and Diabetes Risk Screening Study" (HYDRA) has been identifying 37.8% of patients with hypertension and diabetes to have a positive dipstick test for microalbuminuria on the study day while only 12.5% of these are diagnosed by the doctor as having nephropathy. These patients additionally show a high burden of associated comorbidities and thus call for early detection and intervention especially because effective therapy is available. Although screening for microalbuminuria is recommended in the guidelines the value of a routine screening for microalbuminuria in primary care is under recognized.
authors.affiliation: Institut für Klinische Psychologie und Psychotherapie, TU Dresden.
authors.forename: P
authors.initials: P
authors.lastname: Bramlage
authors.forename: H U
authors.initials: HU
authors.lastname: Wittchen
authors.forename: D
authors.initials: D
authors.lastname: Pittrow
authors.forename: R
authors.initials: R
authors.lastname: Dikow
authors.forename: W
authors.initials: W
authors.lastname: Kirch
authors.forename: H
authors.initials: H
authors.lastname: Lehnert
authors.forename: E
authors.initials: E
authors.lastname: Ritz
mesh_terms: D000328:Adult; D000367:Age Factors; D000419:Albuminuria / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology* / Q000401:mortality / Q000517:prevention & control; D015897:Comorbidity; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000175:diagnosis / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D003928:Diabetic Nephropathies / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control; D005260:Female; D005858:Germany; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control; D008297:Male; D008403:Mass Screening; D015337:Multicenter Studies as Topic; D017410:Practice Guidelines as Topic; D015995:Prevalence; D011320:Primary Health Care; D011507:Proteinuria / Q000150:complications; D012307:Risk Factors; D012737:Sex Factors
chemical_list: D000959:Antihypertensive Agents